Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution

Fig. 3

Intention-to-treat analyses of A) overall survival in 49 patients with BR-A pancreatic cancer and B) overall survival according to CA19-9 at enrollment. Patients with CA19-9 > 400 U/ml showed significantly worse survivals (p = 0.0126). C) Disease-free survival (DFS) and D) locoregional failure-free interval (LFFI) in comparison with distant metastasis-free interval (DMFI). DMFI was significantly worse than LFFI, and comparable to DFS

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us